GREY:BIOAF - Post by User
Post by
prophetoffactzon Jan 17, 2023 3:29pm
148 Views
Post# 35228904
Synergies
SynergiesPeople say they can't see synergies yet xB3 has an affinity for gliolbastoma and Midatech has a glioblastoma drug in clinical trials that is significantly de-risked. BTI has also done work with xB3-Avastin which is used for glioblastoma. Avastin has also shown benefit with the drug lomustine which Midatech is using in combination with its glioblastoma drug.
People say they can't see synergies yet no company in the world has been able to deliver long acting monoclonal antibodies and Midatech has a technology that could do just that. BTI has a significant interest in monoclonal antibodies. Should BTI want to be the company without long acting monoclonal antibodies? Let Denali have it?
"The global demand for monoclonal antibodies market is projected to increase at a CAGR of 12% during the forecast period between 2022 and 2032, reaching a total of US$ 647.01 Billion in 2032, according to a report from Future Market Insights (FMI). From 2017 to 2021, sales witnessed significant growth, registering a CAGR of 6.1%."
People say they can't see synergies yet together BTI and Midatech should be able to enter stronger deals given the increased scale. In the long run, revenue from Midatech's lead drugs could also support a pipeline of development candidates reducing future dilution. Midatech's ultra-rare pediatric brian cancer trial may only need to complete a Phase II and a Phase II filing is anticipated next quarter.